EUVIMEDEUVIMED entdecken
BeobachtungsstudieFallberichtOpen Access · CC BY 4.0

Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones

Micael Widerström, Sara Mörtberg, Mattias Magnusson, Peter Fjällström, Anders F Johansson iD

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad690 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Micael Widerström und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Tularemia, Francisella tularensis, Lymphadenopathy, Bacteremia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research and Development Unit, Region Jämtland-Härjedalen and Region Västerbotten.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fluoroquinolones lack approval for treatment of tularemia but have been used extensively for milder illness. Here, we evaluated fluoroquinolones for severe illness.

Methods

In an observational study, we identified case-patients with respiratory tularemia from July to November 2010 in Jämtland County, Sweden. We defined severe tularemia by hospitalization for >24 hours and severe bacteremic tularemia by Francisella tularensis subsp. holarctica growth in blood or pleural fluid. Clinical data and drug dosing were retrieved from electronic medical records. Chest images were reexamined. We used Kaplan–Meier curves to evaluate time to defervescence and hospital discharge.

Results

Among 67 case-patients (median age, 66 years; 81% males) 30-day mortality was 1.5% (1 of 67). Among 33 hospitalized persons (median age, 71 years; 82% males), 23 had nonbacteremic and 10 had bacteremic severe tularemia. Subpleural round consolidations, mediastinal lymphadenopathy, and unilateral pleural fluid were common on chest computed tomography. Among 29 hospitalized persons with complete outcome data, ciprofloxacin/levofloxacin (n = 12), ciprofloxacin/levofloxacin combinations with doxycycline and/or gentamicin (n = 11), or doxycycline as the single drug (n = 6) was used for treatment. One disease relapse occurred with doxycycline treatment. Treatment responses were rapid, with median fever duration 41.0 hours in nonbacteremic and 115.0 hours in bacteremic tularemia. Increased age-adjusted Charlson comorbidity index predicted severe bacteremic tularemia (odds ratio, 2.7 per score-point; 95% confidence interval, 1.35–5.41). A 78-year-old male with comorbidities and delayed ciprofloxacin/gentamicin treatment died.

Conclusions

Fluoroquinolone treatment is effective for severe tularemia. Subpleural round consolidations and mediastinal lymphadenopathy were typical findings on computed tomography among case-patients in this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TularemiaFrancisella tularensisLymphadenopathyBacteremiaFrancisellaMaleHumansAgedFemaleDoxycyclineFluoroquinolonesLevofloxacinCiprofloxacinTreatment OutcomeGentamicins

Stichwörter der Autor:innen

X raycomputed tomographyfluoroquinolone/therapeutic usetreatment outcometularemia/drug therapy

Substanzen

DoxycyclineFluoroquinolonesLevofloxacinCiprofloxacinGentamicins

Autor:innen und Institutionen

  • Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  • Department of Infectious Diseases, Östersund Hospital, Östersund, Sweden.
  • Department of Radiology, Östersund Hospital, Östersund, Sweden.

ORCID-Profile: Anders F Johansson

Förderung

  • Research and Development Unit
  • Region Jämtland-Härjedalen and Region Västerbotten

Zitieren

APA

Widerström, M., Mörtberg, S., Magnusson, M., Fjällström, P., & Johansson, A. F. (2024). Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad690

Vancouver

Widerström M, Mörtberg S, Magnusson M, Fjällström P, Johansson AF. Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad690

BibTeX
@article{Widerstrm2024,
  author = {Widerström, Micael and Mörtberg, Sara and Magnusson, Mattias and Fjällström, Peter and Johansson, Anders F},
  title = {Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad690}
}
Kostenlos starten →